New structure and operating model 'will prepare EMA for future challenges'
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has published details of its new organizational structure, which it says will allow it to focus on its key tasks and support its role in the EU drug regulatory system. Among the key changes are four new core divisions, improved co-ordination with stakeholders, and the addition of two major advisory functions on policy and program design.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.